A way to modulate RPA–protein interactions in cancer cells, and thereby to disrupt DDR activation, is via specific inhibitors that target the N-terminus or RPA1 (70N) and the C-terminus of RPA2 (32C), which harbor the protein interaction modules (Figure 1). The gene discussed is RPA2; the disease is cancer.